Oncologic outcomes in 408 consecutive patient cohort treated with da Vinci robot-assisted radical prostatectomy

Moreno-Sierra, Jesús; Galante-Romo, M.I.; Senovilla-Perez, J.L.; Redondo-González, Enrique; Galindo-Herrero, I.; Barrera-Ortega, J.; Vives-Dilmes, R.; Ariño-Irujo, J.; Fernández-Montarroso, L.; Fernández-Pérez, Cristina

doi:10.1016/j.acuroe.2019.11.003

Cited by 3 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 1 – 3 Radical prostatectomy (RP) is one of the mainstays of treatment for localized PCa, and the robot-assisted procedure has been adopted as the preferred surgical approach during the last decade. 4 , 5 In this setting, entering the era of precision surgery and individualized medicine, 6 , 7 pretreatment assessment of the clinical and pathological features of patients with localized PCa is of paramount importance to determine their prognosis and design the most optimal and individualized therapeutic strategy. The current established risk stratification system based on serum prostate-specific antigen (PSA) level, biopsy Gleason score, and clinical tumor stage identifies patients with unfavorable preoperative pathological factors and classifies them in low-, intermediate,- and high-risk groups according to pretreatment risk of recurrence.…”

Section: Introductionmentioning

confidence: 99%

Oncological outcomes in robot-assisted radical prostatectomy: the value of PSA density as a preoperative predictive factor

Vives Dilme,

Rivas,

Fernández Hernández

et al. 2024

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Background: Pretreatment assessment of patients diagnosed with localized prostate cancer (PCa) is essential for therapeutic decision-making. Currently available staging systems based on prostate-specific antigen (PSA), Gleason score, and clinical stage allow for determining the prognostic characteristics of these patients. Several studies have evaluated the preoperative use of prostate-specific antigen density (PSAD) as a prognostic factor for further risk stratification. To date, the role of PSAD in this setting is still an object of debate. Objectives: The present analysis aimed to assess the predictive potential of PSAD for adverse oncological outcomes after robot-assisted radical prostatectomy (RARP) and to compare its accuracy to preoperative PSA (pPSA). Design and methods: We retrospectively reviewed 427 patients diagnosed with localized PCa who underwent RARP at a single institution between January 2015 and January 2020. Generating receiver operator characteristic (ROC) curves, calculating areas under the curves (AUCs), and using a linear regression model, we analyzed the association of PSAD and pPSA with postoperative positive surgical margins (PSM), Gleason score ⩾ 7, persistent PSA, and biochemical recurrence (BCR), with a median follow-up of 47 months. Results: PSAD showed a significant association with PSM ( p < 0.0001), PSA persistence ( p < 0.0001), and Gleason ⩾ 7 ( p < 0.0001), without being statistically significant in predicting BCR ( p = 0.098). The predictive value of PSAD was comparable to pPSA for outcomes of PSA persistence (AUC 0.727 versus 0.771) and Gleason ⩾ 7 (AUC 0.683 versus 0.649). Conclusion: PSAD is a predictive factor for postoperative oncological outcomes of PSM, Gleason score ⩾ 7, and persistence of PSA. Despite the need for further studies, PSAD could be useful as a prognostic parameter in conjunction with established staging systems.

show abstract

Section: Introductionmentioning

confidence: 99%

Oncological outcomes in robot-assisted radical prostatectomy: the value of PSA density as a preoperative predictive factor

Vives Dilme,

Rivas,

Fernández Hernández

et al. 2024

Therapeutic Advances in Urology

View full text Add to dashboard Cite

show abstract

“…Currently, PSM rates range from 9%-26% for robot-assisted radical prostatectomy (RARP) [5] . In the last decade, entering the era of precision surgery [6] , RARP has been adopted as the preferred and most frequently used surgical approach [7][8][9][10][11] . Furthermore, robotic surgery allows the integration of novel tools and innovative technologies to plan and guide RP [6] .…”

Section: Introductionmentioning

confidence: 99%

Improving oncological outcomes after robot-assisted radical prostatectomy: what novel tools do we have?

Dilme¹,

Rivas²,

Hernández³

et al. 2022

Mini-invasive Surg

View full text Add to dashboard Cite

The recent application of novel technologies to the robot-assisted radical prostatectomy (RARP) procedure has provided a new perspective and demonstrated potential usefulness in surgical planning, intraoperative navigation, and education of both patients and healthcare professionals, allowing for a patient-tailored prostate cancer (PCa) treatment. Integration of novel techniques into robotic surgery has improved the accuracy of surgery and has demonstrated a potential benefit in functional and oncological outcomes in patients with PCa. However, further randomized and prospective studies are needed to assess and validate the role of these technologies in clinical practice. The aim of this review is to summarize the current evidence on the new emerging techniques, such as three-dimensional (3D) imaging and printing, augmented reality (AR), and confocal microscopy (CM), and their impact on RARP and its oncological outcomes.

show abstract

Principles of prostate cancer surgery

Galante Romo,

Redondo González,

Moreno Sierra

2024

Rev Cancer

View full text Add to dashboard Cite

Oncologic outcomes in 408 consecutive patient cohort treated with da Vinci robot-assisted radical prostatectomy

Cited by 3 publications

References 26 publications

Oncological outcomes in robot-assisted radical prostatectomy: the value of PSA density as a preoperative predictive factor

Oncological outcomes in robot-assisted radical prostatectomy: the value of PSA density as a preoperative predictive factor

Improving oncological outcomes after robot-assisted radical prostatectomy: what novel tools do we have?

Principles of prostate cancer surgery

Contact Info

Product

Resources

About